Tobin Schilke Revance Therapeutics, Inc. (RVNC) insider trading activity

RVNC Quotes by TradingView

Tobin Schilke is CFO of Revance Therapeutics, Inc.. Currently has a direct ownership of 193,666 shares of RVNC, which is worth approximately $497,721. The most recent transaction as insider was on Jun 30, 2022, when has been sold 965 shares (Common Stock) at a price of $11.75 per share, resulting in proceeds of $11,339. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 194K
0% 3M change
112.12% 12M change
Total Value Held $497,721

Tobin Schilke Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jun 30 2022
BUY
Grant, award, or other acquisition
$11,339 $11.75 p/Share
965 Added 1.5%
63,490 Common Stock
Mar 15 2022
SELL
Payment of exercise price or tax liability
$41,165 $15.79 p/Share
2,607 Reduced 4.0%
62,525 Common Stock
Feb 15 2022
SELL
Payment of exercise price or tax liability
$39,035 $13.35 p/Share
2,924 Reduced 4.3%
65,132 Common Stock
Feb 02 2022
BUY
Grant, award, or other acquisition
-
42,349 Added 28.66%
105,430 Common Stock
Dec 31 2021
BUY
Other acquisition or disposition
$5,603 $13.87 p/Share
404 Added 0.59%
68,056 Common Stock
Dec 15 2021
SELL
Payment of exercise price or tax liability
$24,772 $15.92 p/Share
1,556 Reduced 2.25%
67,652 Common Stock
Jun 30 2021
BUY
Other acquisition or disposition
$10,744 $24.09 p/Share
446 Added 0.64%
69,208 Common Stock
Feb 15 2021
SELL
Payment of exercise price or tax liability
$76,973 $28.97 p/Share
2,657 Reduced 3.72%
68,762 Common Stock
Feb 02 2021
BUY
Grant, award, or other acquisition
-
22,620 Added 24.05%
71,419 Common Stock
Dec 31 2020
BUY
Other acquisition or disposition
$10,530 $21.36 p/Share
493 Added 1.0%
48,799 Common Stock
Dec 15 2020
SELL
Payment of exercise price or tax liability
$41,623 $26.75 p/Share
1,556 Reduced 3.12%
48,306 Common Stock
Sep 30 2020
SELL
Payment of exercise price or tax liability
$136,912 $25.14 p/Share
5,446 Reduced 9.85%
49,862 Common Stock
Sep 30 2020
BUY
Grant, award, or other acquisition
-
15,750 Added 22.16%
55,308 Common Stock
TS

Tobin Schilke

CFO
Nashville, TN

Track Institutional and Insider Activities on RVNC

Follow Revance Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RVNC shares.

Notify only if

Insider Trading

Get notified when an Revance Therapeutics, Inc. insider buys or sells RVNC shares.

Notify only if

News

Receive news related to Revance Therapeutics, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on RVNC